Could Colombia’s pharmacy cannabis model become the template for all of Latin America?
Colombia’s Colombia cannabis pharmacy sales framework took a decisive leap forward in October 2025, when the government issued Decree 1138 — a sweeping update to the country’s health-sector regulations that officially authorized the sale of dried cannabis flower through licensed pharmacies and drugstores under medical prescription. For the first time in Colombia’s history, patients do not have to rely solely on oils, capsules, or extracts: they can now walk into a licensed pharmacy, hand over a valid prescription, and receive the natural flower in a fully regulated, traceable transaction.
This shift matters well beyond Colombia’s borders. With a cannabis cultivation market projected to reach $2 billion USD by 2030, and with over 3,000 active licenses already issued, Colombia is positioned as a dominant low-cost producer in Latin America. Decree 1138 transforms the country from a primarily export-focused supplier into a nation with a functioning domestic medical market — a model that regulators across Latin America are watching closely.
Key Takeaways
- Colombia’s Decree 1138, issued October 27, 2025, authorizes pharmacy sales of cannabis flower under medical prescription for the first time.
- Eligible conditions include chronic pain, sleep disorders, Parkinson’s disease, multiple sclerosis, and other central nervous system disorders.
- For the first two years, only micro, small, and medium-sized Colombian cultivators can supply the domestic market — a deliberate social equity measure.
- INVIMA must publish eight technical guidelines (GMP, labeling, dispensing, traceability, and clinical standards) by March 2026.
- Full traceability from cultivation to dispensing is mandated via interoperability with the Ministry of Justice’s SEED tracking system.
- Colombia’s cannabis cultivation market is projected to grow at a 23.1% CAGR through 2030, reaching $2.02 billion USD.
What Colombia Cannabis Pharmacy Sales Now Allow Under Decree 1138
Before Decree 1138, Colombian patients could access cannabis-based medicines in pharmaceutical forms — tinctures, capsules, suppositories, oils — but flower itself was not recognized as a finished medicinal product eligible for pharmacy dispensing. Decree 1138 changes that by formally amending portions of Decree 780 of 2016 (the foundational health-sector regulatory framework) to recognize dried cannabis flower as a valid finished product for medical use.
Under the new framework, licensed pharmacies and drugstores may dispense cannabis flower directly to patients presenting a valid medical prescription. The decree covers both psychoactive and non-psychoactive preparations, and also extends provisions to magistral (compounded) preparations for both human and veterinary use — all of which must be produced using Colombian-grown raw materials exclusively. Imported cannabis derivatives are prohibited from use in domestic products, a measure designed to protect Colombia’s sovereign production base.
The practical effect is significant: Colombia’s pharmacy network, which reaches patients across urban and rural areas alike, becomes the primary access point for medical cannabis flower. This is a fundamentally different distribution model than the one that previously relied on specialty importers or online-only dispensaries. According to International Cannabis Business Conference, this marks a foundational shift in how Colombia’s 50+ million citizens can access cannabis-based therapies.
Who Qualifies and How Patients Access Cannabis Flower in Pharmacies
To access cannabis flower at a Colombian pharmacy under Decree 1138, a patient must present a valid medical prescription issued by a licensed healthcare professional. The decree does not establish a rigid list of covered diagnoses, but regulatory guidance and prior practice identify several key qualifying conditions:
- Chronic pain (including neuropathic and cancer-related pain)
- Sleep disorders
- Parkinson’s disease
- Multiple sclerosis
- Other conditions affecting the central nervous system
Once the prescription is presented, patients may legally purchase the flower and consume it through smoking or vaporization. The decree does not impose per-purchase quantity limits at the time of issuance, but those specifics will be detailed in INVIMA’s forthcoming technical guidelines expected by March 2026.
Traceability is central to the access model. Each batch of cannabis flower dispensed through the pharmacy system must be linked to the Ministry of Justice’s SEED tracking platform, which follows the plant from licensed cultivation through processing and delivery. This end-to-end chain of custody is designed to prevent diversion to unregulated markets and to give INVIMA and health authorities real-time visibility into the supply.
What Operators Need to Know: Licensing and Compliance Requirements
For cannabis operators — whether cultivators, processors, or pharmacy distributors — Decree 1138 introduces a set of layered compliance obligations that require careful planning.
Manufacturing and GMP certification. Cannabis flower products may only be produced in pharmaceutical establishments certified by INVIMA. Production must occur under the supervision of a qualified pharmaceutical chemist. INVIMA is required to publish a Technical Guide for Good Manufacturing Practices (GMP) specifically applicable to cannabis flower within five months of the decree’s issuance.
100% Colombian raw materials. All raw materials used in finished cannabis flower products must originate from licensed Colombian crops. The use of imported cannabis derivatives is prohibited. This applies equally to products intended for human use and magistral veterinary preparations, ensuring Colombia’s production sovereignty and domestic supply chain integrity.
Priority licensing for small growers. The Ministry of Justice has five months from the decree’s issuance to develop a simplified licensing pathway for micro, small, and medium-sized cultivators. During the first two years of implementation, only these smaller operators are permitted to supply the domestic market. Large-scale producers are excluded from the domestic flower market during this transition window, though they may continue exporting.
INVIMA’s eight-guideline framework. INVIMA is charged with publishing eight technical guidelines before March 2026 covering: Good Manufacturing Practices (GMP), clinical trial standards, labeling requirements, dispensing protocols, traceability specifications, advertising controls, pharmacovigilance standards, and import/export controls for research purposes.
Transition timeline. The full regulatory framework carries a two-year implementation window. Operators should treat the March 2026 INVIMA guideline publication as the effective start date for detailed compliance planning, with full enforcement expected progressively through 2027.
For operators seeking to align their internal tracking and compliance systems ahead of the INVIMA deadlines, cannabis compliance software built for Latin American regulatory environments can provide the seed-to-sale traceability infrastructure the decree requires.
Colombia Cannabis Pharmacy Sales as a Model for Latin America
Colombia’s pharmacy dispensing framework does not exist in isolation — it is part of a broader, accelerating shift in Latin American cannabis policy that positions the region as the next major growth market for medical cannabis.
Colombia’s export figures illustrate the trajectory: cannabis exports reached $10.8 million USD in 2023, up from $8.4 million in 2022. Brazil, Australia, and Germany are the three largest importers of Colombian cannabis products. But until Decree 1138, Colombia had no organized domestic pharmacy channel — exports were the primary commercial outlet for licensed producers.
The domestic pharmacy model changes the calculus. Colombia now has the full architecture of a regulated medical cannabis market: licensed cultivation, pharmaceutical-grade processing, INVIMA-certified manufacturing, pharmacy dispensing, and SEED-based traceability. This is the same integrated model that Germany, Australia, and Canada have implemented — and it mirrors the structure regulators in Brazil, Mexico, Argentina, and Peru are working toward.
The social equity dimension of Decree 1138 is also notable for its regional originality. By reserving the domestic market for small and medium cultivators for two years, Colombia is explicitly using cannabis policy as a rural economic development tool — one with direct precedent in its peace process commitments to coca-growing communities seeking legal alternatives. That model is closely watched by neighboring Andean nations with similar agricultural and social dynamics.
For international operators considering Colombia market entry, the opportunity is clear: the domestic channel is opening, but the first two years belong to Colombian small growers. The long-term play lies in positioning for the post-transition phase, when the domestic market opens fully to larger operators — backed by a cultivation sector that Grand View Research projects to grow at a 23.1% CAGR through 2030.
Frequently Asked Questions
What is the Colombia cannabis pharmacy sales Decree 1138?
Decree 1138 is a Colombian government regulation issued October 27, 2025, that officially authorizes Colombia cannabis pharmacy sales of dried flower under medical prescription. The decree amends the prior health framework (Decree 780 of 2016) to recognize cannabis flower as a finished medicinal product eligible for dispensing through licensed pharmacies and drugstores. It also establishes traceability requirements via the SEED system, mandates 100% Colombian-origin raw materials, and gives priority domestic market access to micro, small, and medium cultivators for two years during the transition period.
Who can buy cannabis flower at a pharmacy in Colombia?
Any patient with a valid medical prescription from a licensed Colombian healthcare provider may purchase cannabis flower at an authorized pharmacy or drugstore. Common qualifying conditions include chronic pain, sleep disorders, Parkinson’s disease, multiple sclerosis, and central nervous system disorders. The prescribing physician determines appropriateness, and the dispensing pharmacy must log the transaction through INVIMA-compliant traceability systems linked to the Ministry of Justice’s SEED platform.
What does Decree 1138 mean for cannabis operators and investors in Latin America?
For operators, Decree 1138 creates a new domestic distribution channel but with strict requirements: INVIMA-certified GMP manufacturing, pharmaceutical chemist oversight, 100% Colombian raw materials, and full SEED-based traceability. For investors, the decree signals that Colombia’s cannabis industry is maturing from an export-only model to a fully integrated medical market — with a cultivation sector projected to reach $2.02 billion USD by 2030. The two-year window prioritizing small cultivators shapes the near-term opportunity but does not close the door to larger operators preparing for post-transition market entry.
Entering Colombia’s Cannabis Market?
GrowerIQ helps cannabis operators stay compliant across Latin America’s evolving regulatory frameworks.
REQUEST DEMOAbout GrowerIQ
GrowerIQ is changing the way producers use software - transforming a regulatory requirement into a robust platform to learn, analyze, and improve performance.
To find out more about GrowerIQ and how we can help, fill out the form to the right, start a chat, or contact us.